RMRowan Mesilhy

Rowan Mesilhy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rowan Mesilhy has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and safety of ropeginterferon in myeloproliferative neoplasms: a systematic review and meta-analysis

    by Aadhila Abbas Manthiri, Leen Haj Saleh, Marrita Rabadi, Ayman Dalol, Rowan Mesilhy, Usra Elshaikh, Abdulrahman F. Al-Mashdali, Mohammed Abdulgayoom, Shehab F. Mohamed

    Background: Ropeginterferon alfa-2b (ropegIFN-α2b or ropeginterferon) has emerged as a therapeutic option for patients with myeloproliferative neoplasms, particularly polycythemia vera (PV), with potential disease-modifying effects. This systematic review aimed to evaluate the efficacy and safety of ropeginterferon across clinical and real-world studies. Methods: A systematic search of PubMed, Embase, and Web of Science was conducted to identify studies reporting clinical outcomes of ropeginterferon in patients with MPNs. An additional PubMed search was performed to capture recently published studies. Eligible studies were screened according to predefined inclusion criteria. Data on hematologic, molecular, clinical, and safety outcomes were extracted and narratively synthesized. A proportional meta-analysis was conducted for selected outcomes, including complete hematologic response (CHR), partial molecular response (PMR), and grade ≥3 cytopenias. Results: A total of 18 studies involving 1,836 patients were included. Pooled analysis demonstrated that CHR rates increased over time, from 26% at 3 months to 59% at 12 months, with an overall pooled estimate of 56% (95% CI: 46%–66%). PMR was achieved in 37% of patients (95% CI: 20%–59%), although with substantial heterogeneity. Molecular responses were supported by consistent reductions in JAK2 allele burden across studies. Clinical outcomes showed improvements in spleen size and symptom burden in several cohorts. Ropeginterferon was generally well tolerated. The pooled proportion of grade ≥3 cytopenias was 3% (95% CI: 1%–10%), and severe hepatotoxicity was uncommon, typically occurring in ≤5% of patients. Most adverse events were low grade, with infrequent treatment discontinuations. Conclusion: RopegIFN-α2b demonstrates favorable efficacy and safety profiles in patients with MPNs, especially in PV, with evidence of progressive hematologic and molecular responses over time. These findings support its role as a potentially disease-modifying therapy, although further standardized and long-term studies, focusing on ET and MF, are needed. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261337306 , identifier CRD420261337306.

  • Open Access

    BRAF Mutations in Myeloid Neoplasms: Prevalence, Co-Mutation Landscape, and Clinical Outcomes—A Comprehensive Review

    by Shehab F. Mohamed, Ali Mohamed, Mohamed Fawzi Mudarres, Azza E. A. Abdalla, Abdulrahman F. Al-Mashdali, Mohammed Abdulgayoom, Rowan Mesilhy, Tareq Abuasab, Honar Cherif, Gautam Borthakur

    Background: BRAF is a core component of the RAS–MAPK signaling pathway and an established oncogenic driver in several solid tumors and selected hematologic malignancies. In myeloid neoplasms, BRAF mutations are rare, and their prevalence, molecular context, and clinical significance remain incompletely defined. Available evidence is scattered across heterogeneous reports involving acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, and overlap myelodysplastic/myeloproliferative neoplasms, with variable descriptions of mutation subtypes, co-mutational profiles, cytogenetic associations, therapeutic approaches, and clinical outcomes. To address these gaps, this review synthesizes data from the published literature up to 2025, summarizing the distribution, genetic landscape, and clinical impact of molecularly confirmed BRAF mutations across the spectrum of myeloid neoplasms. Results: Across published cohorts, BRAF mutations occurred in less than 1% of unselected myeloid neoplasms, with enrichment in chronic myelomonocytic leukemia and therapy-related or secondary acute myeloid leukemia. Both V600E and non-V600E variants were observed, typically within a complex genomic background involving ASXL1, TET2, DNMT3A, SRSF2, and RAS-pathway mutations. Acute myeloid leukemia cases showed poor prognosis, with median overall survival measured in months, whereas myelodysplastic syndromes and chronic myelomonocytic leukemia demonstrated relatively longer survival. Targeted MAPK inhibition produced hematologic responses in selected cases but rarely resulted in durable molecular clearance. Conclusions: BRAF mutations in myeloid neoplasms are rare, heterogeneous, and usually represent secondary events in clonal evolution. Although mutation clearance appears prognostically relevant, current targeted approaches provide limited durability, underscoring the need for prospective studies in this setting.

  • Open Access

    Comparative survival outcomes between therapy-related and de novo acute lymphoblastic leukemia in adults: a systematic review and meta-analysis

    by Rowan Mesilhy, Muhammad Naseem Khan, Asma Syed, Razan Hourani, Honar Cherif, Yasmin Elsalkawi, Hafsa Khalid, Abdulrahman Al-Mashdali, Dina Soliman, Deena Mudwai, et al.

    Therapy-related acute lymphoblastic leukemia (t-ALL) is an aggressive subtype of ALL that arises after cytotoxic therapy. It is associated with adverse cyt

  • Open Access

    Determinants of Prolonged Antibiotic Administration in Culture-Negative Evaluations of Early-Onset Neonatal Meningitis: A Retrospective Cohort Study

    by Rowan Mesilhy, Ibrahim Safra, Shaikha Alnaimi, Ala Ali, Rayan Terkawi, Mohammed Gaffari, Talal Alhendawi, Anvar P. Vellamgot, Ashraf Gad

    Background: Early-onset neonatal meningitis (EONM) is a rare but serious condition where antibiotics are often given for extended periods, even without a positive cerebrospinal fluid (CSF) culture. The reasons for this prolonged treatment are unknown. Methodology: This study, conducted at the Women’s Wellness and Research Center, Doha, retrospectively analyzed the determinants of prolonged antibiotic therapy among neonates with sterile CSF cultures during the first week of life, born during 2015 to 2018. Results: Of 315 neonates without confirmed meningitis, 96 (30.5%) received prolonged antibiotic therapy. These infants had significantly lower birth weights (2790 g vs. 3170 g) and gestational ages (36.7 weeks vs. 38.5 weeks). They were more likely to require respiratory support, appear ill, and have laboratory abnormalities, including neutropenia, positive blood cultures (36.5% vs. 0.9%), elevated C-reactive protein (CRP), and higher CSF protein. Multivariable analysis identified low Apgar scores (Adjusted Odds Ratio (aOR), 2.82), positive blood cultures (aOR, 118.48), traumatic lumbar puncture (LP) (aOR, 2.14), CRP levels ≥ 50 mg/L (aOR, 2.60), delayed LP (OR, 8.28), and elevated cerebrospinal fluid white cell counts (aOR, 5.47) as independent predictors of prolonged antibiotic use. Conclusions: Prolonged antibiotic use in neonates with sterile CSF cultures and suspected EONS is common and may be driven by certain clinical and laboratory indicators of illness severity and inflammation. Identifying these predictors can support risk-stratified treatment decisions, promoting safer antimicrobial stewardship.


  • Open Access

    Impact of Apolipoprotein A on Cardiac and Neural Abnormalities

    by Rowan Mesilhy, Zainab Nurulhaque, Patrick Burgon, Shona Pedersen, Rafif Al Saady

    Apolipoprotein A (ApoA), an integral component of high-density lipoprotein (HDL) particles, plays a vital role in the transport and metabolism of lipids. It is implicated in both cardiovascular (CVD) and neurological diseases. In the context of CVD, ApoAs are pivotal in facilitating the reverse transport of cholesterol, mitigating inflammation, and preserving endothelial function. These char- acteristics highlight the crucial role of ApoA in averting the onset of CVDs. Moreover, ApoA has been implicated in the pathogenesis of several diseases, such as Alzheimer's disease (AD), Parkin- son's disease (PD), and multiple sclerosis (MS). Apart from its role in lipid metabolism, recent stud- ies have indicated the involvement of ApoA in neuroprotection, amyloid-beta clearance, and regu- lation of neuroinflammation. This paper addresses the research question: "How do different isoforms of Apolipoprotein A influence the development and progression of cardiovascular and neurological diseases, and what are the potential therapeutic implications of targeting ApoA in these conditions?" By providing a comprehensive review of current knowledge, this paper empha- sizes the importance of ApoA in understanding the intricate connections between cardiovascular and neurological health, suggesting that ApoA-targeted interventions may help treat diseases in both domains.

  • Innovations in Tuberculosis Disease Screening

    by Duaa Yousif, Rowan Mesilhy, Roaa Aly, Salma Hegazi, Zahra Yousif, Farhan S. Cyprian, Abdallah M. Abdallah


  • Open Access

    Diabetic Foot Ulcer Wound Healing and Tissue Regeneration: Signaling Pathways and Mechanisms

    by Salma Hegazi, Roaa Aly, Rowan Mesilhy, Hesham Aljohary

    This chapter digs into the complexities of diabetic foot ulcer (DFU) wound healing, encompassing cellular responses from fibroblasts, keratinocytes, and macrophages, as well as humoral responses involving the release of growth factors and cytokines. The normal wound healing process is hindered in diabetics by factors like infections, venous insufficiency, impaired oxygenation, age-related changes, immune dysfunction, and a dry environment, contributing to delayed and challenging wound healing. The discussion then focuses on the intricate interplay of signaling cascades, including PI3K/Akt, MAPK/ERK, and Wnt/β-catenin, in the pathology of DFUs. Diabetes induces disruptions in the PI3K/Akt pathway, impeding cell migration and angiogenesis due to compromised insulin signaling and increased oxidative stress. Abnormalities in the MAPK pathway, essential for inflammation and tissue remodeling, further impact wound closure in DFUs. Additionally, downregulation of the Wnt/β-catenin pathway, crucial for tissue regeneration, contributes to immune dysfunction, delaying healing in diabetic wounds. Finally, the chapter explores multifaceted factors contributing to the pathogenesis of DFUs, including epigenetic modifications, oxidative stress, advanced glycation end products (AGEs), the polyol pathway, diacylglycerol-protein kinase C (DAG-PKC) activation, and the nitric oxide (NO) pathway. Persistent hyperglycemia in diabetes hinders wound healing, causing chronic ulcers and complications. Addressing these mechanisms is crucial for revolutionizing management.